HighVista Strategies LLC grew its position in Scholar Rock Holding Corporation (NASDAQ:SRRK – Free Report) by 90.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 59,573 shares of the company’s stock after buying an additional 28,343 shares during the period. HighVista Strategies LLC owned approximately 0.06% of Scholar Rock worth $2,218,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Scholar Rock by 1.1% during the third quarter. Vanguard Group Inc. now owns 4,914,927 shares of the company’s stock worth $183,032,000 after acquiring an additional 53,333 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Scholar Rock by 124.5% during the 3rd quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock valued at $169,289,000 after purchasing an additional 2,521,022 shares in the last quarter. Bellevue Group AG grew its position in shares of Scholar Rock by 10.1% in the 3rd quarter. Bellevue Group AG now owns 3,244,537 shares of the company’s stock valued at $120,827,000 after purchasing an additional 297,242 shares during the period. Eventide Asset Management LLC lifted its stake in Scholar Rock by 9.5% in the second quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company’s stock valued at $103,192,000 after buying an additional 251,638 shares in the last quarter. Finally, Holocene Advisors LP bought a new stake in shares of Scholar Rock during the third quarter worth $91,670,000. Institutional investors and hedge funds own 91.08% of the company’s stock.
Insider Transactions at Scholar Rock
In other Scholar Rock news, insider Akshay Vaishnaw sold 20,438 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $872,702.60. Following the transaction, the insider owned 595,767 shares of the company’s stock, valued at $25,439,250.90. The trade was a 3.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Vikas Sinha sold 16,755 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total value of $715,438.50. Following the completion of the sale, the chief financial officer directly owned 583,245 shares of the company’s stock, valued at approximately $24,904,561.50. The trade was a 2.79% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 208,470 shares of company stock valued at $9,201,778. 13.30% of the stock is owned by insiders.
Analyst Ratings Changes
Get Our Latest Stock Analysis on Scholar Rock
Scholar Rock Stock Down 4.3%
Scholar Rock stock opened at $40.01 on Monday. The company has a fifty day simple moving average of $45.21 and a 200 day simple moving average of $39.68. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a 1-year low of $22.71 and a 1-year high of $49.82. The company has a market cap of $4.60 billion, a P/E ratio of -11.66 and a beta of 0.70.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.10. During the same quarter last year, the company earned ($0.64) EPS. Research analysts anticipate that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current fiscal year.
About Scholar Rock
Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.
The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).
Read More
- Five stocks we like better than Scholar Rock
- The $8,000 Gold Call Every Retirement Saver Needs to Read Right Now
- A personal warning from Martin Weiss (Please read)
- Elon Musk: This Could Turn $100 into $100,000
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- America’s gold reserves are priced at $42. The real price is $6,000+.
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.
